clinical trial · NCT06939816
Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)
Enyo Pharma·phase2·terminated·n = 10
Chronic Kidney Disease Stage 2Chronic Kidney Disease Stage 3Metabolic Dysfunction-Associated SteatohepatitisVonafexor low doseVonafexor high dose
brief summary
This study is designed to establish the effect of 2 doses of vonafexor on the kidney. This will be investigated in subjects with mild or moderate reduced estimated glomerular filtration rate (eGFR) and suspected MASH. In addition, the non-invasive multiparametric magnetic resonance imaging assessment of functional and structural changes in the kidney and in the liver will be investigated.
started
Jul 1, 2025
primary completion
Dec 22, 2025
completion
Mar 13, 2026
last updated
Apr 23, 2026
detailed description
This is a phase 2, open-label, two-dose, randomized, parallel arms, single center study where subjects are participating for up to 32 weeks:
* Screening: 4 weeks * Treatment: 16 weeks * Follow-up: 12 weeks
official title
A Study to Assess the Effect of Vonafexor on Kidney Function in Subjects With Impaired Renal Function and Suspected MASH
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol